12.44
price up icon6.23%   0.73
pre-market  Pre-mercato:  12.64   0.20   +1.61%
loading
Precedente Chiudi:
$11.71
Aprire:
$11.73
Volume 24 ore:
779.72K
Relative Volume:
0.81
Capitalizzazione di mercato:
$975.05M
Reddito:
$54.55M
Utile/perdita netta:
$-193.57M
Rapporto P/E:
-4.3045
EPS:
-2.89
Flusso di cassa netto:
$-181.86M
1 W Prestazione:
+7.06%
1M Prestazione:
+2.47%
6M Prestazione:
-36.24%
1 anno Prestazione:
-34.28%
Intervallo 1D:
Value
$11.46
$12.90
Intervallo di 1 settimana:
Value
$11.34
$12.90
Portata 52W:
Value
$8.18
$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name
Nome
Nurix Therapeutics Inc
Name
Telefono
(415) 660-5320
Name
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Name
Dipendente
286
Name
Cinguettio
Name
Prossima data di guadagno
2025-04-09
Name
Ultimi documenti SEC
Name
NRIX's Discussions on Twitter

Confronta NRIX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NRIX
Nurix Therapeutics Inc
12.44 975.05M 54.55M -193.57M -181.86M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-17 Iniziato Leerink Partners Market Perform
2024-12-10 Iniziato BTIG Research Buy
2024-12-06 Iniziato BMO Capital Markets Outperform
2024-10-24 Iniziato UBS Buy
2024-10-11 Iniziato Jefferies Buy
2024-09-06 Ripresa Robert W. Baird Outperform
2024-07-31 Iniziato Truist Buy
2023-06-26 Ripresa Oppenheimer Outperform
2023-03-09 Iniziato Barclays Overweight
2023-02-28 Iniziato Oppenheimer Outperform
2022-10-11 Iniziato Morgan Stanley Equal-Weight
2022-05-31 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-02-10 Iniziato Wells Fargo Equal Weight
2021-12-29 Iniziato H.C. Wainwright Buy
2021-10-14 Iniziato SVB Leerink Outperform
2021-06-04 Ripresa Robert W. Baird Outperform
2021-04-30 Ripresa Piper Sandler Overweight
2021-04-30 Iniziato RBC Capital Mkts Outperform
2021-04-14 Iniziato Berenberg Buy
2020-11-19 Iniziato Robert W. Baird Outperform
2020-08-18 Iniziato JP Morgan Overweight
2020-08-18 Iniziato Needham Buy
2020-08-18 Iniziato Piper Sandler Overweight
2020-08-18 Iniziato Stifel Buy
Mostra tutto

Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie

pulisher
Jun 18, 2025

Analysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO) - The Globe and Mail

Jun 18, 2025
pulisher
Jun 17, 2025

Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conf - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

NuCana (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

(NRIX) Investment Analysis - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 14, 2025

Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.9%Here's What Happened - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 14, 2025

Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NRIX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics (NRIX) Shares Dip After Trial Update on Bexob - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix stock drops on new trial data for lead drug (NRIX:NASDAQ) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Transcript : Nurix Therapeutics, Inc.Special Call - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics Announces Positive Phase 1 Trial Results - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | NRIX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenströ - The Manila Times

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: Nurix Cancer Drug Achieves Complete Response in Hard-to-Treat Blood Cancers, New Trial Data Shows - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Nurix Therapeutics reports new KLHDC2 inhibitors - BioWorld MedTech

Jun 11, 2025
pulisher
Jun 10, 2025

Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics, Inc. to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg Being Presented At the 30Th European Hematology Association Congress - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host Webcast on Phase 1 Clinical Trial Data for Bexobrutideg (NX-5948) at EHA2025 - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 ... - Bluefield Daily Telegraph

Jun 06, 2025
pulisher
Jun 06, 2025

Bexobrutideg Phase 1 Trial Shows Promise in Blood Cancer Treatment at EHA Congress | NRIX Stock News - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpHere's Why - MarketBeat

Jun 06, 2025
pulisher
Jun 05, 2025

Stifel Maintains Buy Rating on Nurix (NRIX) Stock - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Two Sigma Investments LP - MarketBeat

Jun 04, 2025
pulisher
Jun 03, 2025

(NRIX) On The My Stocks Page - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Position Reduced by Nuveen Asset Management LLC - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Sanofi exercises option to license STAT6 program from Nurix collaboration - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 02, 2025

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6 - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Exercises License Extension Option To Nurix'S Stat6 Program - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaborat - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaboration | NRIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Exercises License Extension Option to Nurix's STAT6 Program | NRIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Nurix secures additional $15 million from Sanofi license deal - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Bets Big on Nurix: $465M Deal for Revolutionary Inflammation Drug That Could Transform Asthma Treatment - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Wellington Management Group LLP - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%Time to Buy? - MarketBeat

Jun 01, 2025
pulisher
May 30, 2025

Millennium Management LLC Has $7.99 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

May 30, 2025
pulisher
May 28, 2025

Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

May 28, 2025

Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):